Matthew L. Posard - Aug 12, 2024 Form 4 Insider Report for HALOZYME THERAPEUTICS, INC. (HALO)

Role
Director
Signature
/s/ James Oehler, Attorney-in-Fact
Stock symbol
HALO
Transactions as of
Aug 12, 2024
Transactions value $
-$1,689,294
Form type
4
Date filed
8/14/2024, 04:57 PM
Previous filing
Jun 17, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HALO Common Stock Sale -$557K -10K -10.02% $55.72 89.8K Aug 12, 2024 Direct F1, F2
transaction HALO Common Stock Sale -$562K -10K -11.14% $56.19 79.8K Aug 13, 2024 Direct F2, F3
transaction HALO Common Stock Sale -$570K -9.88K -12.39% $57.70 69.9K Aug 14, 2024 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a weighted average sales price per share. The shares were sold at prices ranging from $55.70 to $55.825. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F2 Includes 20,722 stock units that are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are scheduled to be released to the reporting person following completion of service as a director.
F3 Represents a weighted average sales price per share. The shares were sold at prices ranging from $56.058 to $56.26. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.